Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to analyze the safety of 90-min intravenous rapid infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma and to provide evidence for the applicability of rapid infusion regimens in chemotherapy in China.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Treatments: Obinutuzumab

Criteria

Inclusion Criteria:

• Clinical diagnosis of B-cell lymphoma and with indications for obinutuzumab treatment

• No significant organ damage

• ECOG score of 0-2;

• Life expectancy ≥ 6 months

• Informed consent

Exclusion Criteria:

• Pregnant or lactating

• Serologically tested positive for human immunodeficiency virus or hepatitis B virus infection but had not received treatment

• Severe hepatic or renal insufficiency

• Severe cardiovascular disease.